S$0.435 -0.0 -1.1%
Last Trade - 1:54am
| Market Cap | £321.0m |
| Enterprise Value | £273.8m |
| Revenue | £37.0m |
| Position in Universe | 1522nd / 6015 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 63.2 | 65.7 | 68.9 | 61.4 | 61.3 | 75.9 | 57.1 | 59.9 | +3.7% | ||
| +28.3 | -4.2 | +0.1 | -14.3 | -9.8 | +23.6 | -26.4 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
TalkMed Group Limited is a Singapore-based investment holding company. The Company's principal activities are the provision of medical oncology services and stem cell transplant services. The Company's segments include Oncology services and Stem cells services. Its doctors provide tertiary healthcare services in the fields of medical oncology, stem cell transplant and palliative care to the oncology patients in the private sector in Singapore through Parkway Cancer Centre (PCC). Its clinical functions include attending to patients, examination and administering medical treatment to patients and performing minor outpatient surgical procedures, prescribing medicines and investigations, such as laboratory tests or diagnostic procedures. These clinical functions also include the review of investigation results and follow-up care with the patient. It provides medical oncology services and palliative care services with approximately 13 doctors at over eight clinics.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | September 10, 2013 |
| Public Since | January 30, 2014 |
| No. of Shareholders: | 930 |
| No. of Employees: | 53 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | |
| Exchange | Singapore Exchange Securities Trading Ltd |
| Shares in Issue | 1,318,054,779 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 101 Thomson Road #09-02 United Square, 307591, Singapore |
| Web | http://www.talkmed.com.sg/ |
| Phone | +65 6 2586918 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 1:54am, shares in Talkmed are trading at S$0.435, giving the company a market capitalisation of £321.0m. This share price information is delayed by 15 minutes.
Shares in Talkmed are currently trading at S$0.435 and the price has moved by -12.87% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Talkmed price has moved by -24.94% over the past year.
Of the analysts with advisory recommendations for Talkmed, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Talkmed is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Talkmed is scheduled to issue upcoming financial results on the following dates:
The Talkmed dividend yield is 4.32% based on the trailing twelve month period.
Last year, Talkmed paid a total dividend of 0.02, and it currently has a trailing dividend yield of 4.32%. Looking ahead, Talkmed has not announced an ex-dividend date yet.
Talkmed has yet to annouce their ex-dividend date. The historic dividend yield on Talkmed shares is currently 4.32%.
To buy shares in Talkmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Talkmed are currently trading at S$0.435, giving the company a market capitalisation of £321.0m.
Here are the trading details for Talkmed:
Based on an overall assessment of its quality, value and momentum, Talkmed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Talkmed are currently priced at S$0.435. At that level they are trading at 11.36% discount to the analyst consensus target price of 0.00.
Analysts covering Talkmed currently have a consensus Earnings Per Share (EPS) forecast of 0.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Talkmed. Over the past six months, the relative strength of its shares against the market has been -25.38%. At the current price of S$0.435, shares in Talkmed are trading at 0.24% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Talkmed PE ratio based on its reported earnings over the past 12 months is 21.15. The shares are currently trading at S$0.435.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Talkmed's management team is headed by:
Here are the top five shareholders of Talkmed based on the size of their shareholding:
